Drugs / Tandospirone

Trials 3 · a red edge is where a trial was stopped

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT03667677 Feb 2019 → Feb 2020 anxiety, hypertensive disorder Chongqing Medical University Unknown No outcome recorded
Phase 4 NCT03151382 May → Dec 2017 Alzheimer disease Zhejiang Provincial People's Hospital Unknown No outcome recorded
Phase 4 NCT02040883 Feb → Dec 2014 schizophrenia Qingyun Yin Unknown No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT01614041 Comparator Jan 2012 → Sep 2018 generalized anxiety disorder Marubeni Pharmaceuticals (Suzhou) Co., Ltd. Completed No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Tandospirone ClinicalTrials.gov intervention name — accepted as the source's own label NCT02040883
3

NCT03151382

NCT01614041

NCT03667677

Known as Metanopirone ChEMBL registry synonym — accepted as the source's own label CHEMBL274047
Known as Sediel ChEMBL registry synonym — accepted as the source's own label CHEMBL274047
Known as SM-3997 ChEMBL registry synonym — accepted as the source's own label CHEMBL274047
Known as SM-3997 CITRATE ChEMBL registry synonym — accepted as the source's own label CHEMBL274047
Known as Tandospirona ChEMBL registry synonym — accepted as the source's own label CHEMBL274047
Known as Tandospirone Citrate “Drug: Tandospirone CitrateNCT03151382
Known as TANDOSPIRONE HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL274047
Action Activate “5-Hydroxytryptamine 1A (5-HT1A) receptor partial agonist tandospirone” NCT02040883
Modality Small molecule CHEMBL274047
Route Oral “Usual dose treatment of Tandospirone, oral, 30 mg/day” NCT01614041